10579510 - GAU: 1647

10/579510

IAP20 Rec'd PET/PTO 16 MAY 2006

"Express Mail" mailing label numberEV_393133345_US
Date of Deposit May 16,2006
U ·
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
QUEEN THOME Green Ihrme)
Printed Name Signature

PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: BEALS John Michael

> For: MUTEINS OF FIBROBLAST GROWTH FACTOR 21

Docket No.: X-16280

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner. together with copies of PTO-892 forms submitted to Applicants by Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted.

Lynn D. Apelgren Attorney for Applicant(s) Registration No. 45,341 Phone: 317-276-6501

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

X-16280

FORM PTO 1449 (modified)

INFORMATION DISCLOSURE CITATION

WO 01/18209

WO 01/32678

BB

BC

IAP20 Rec'6 PCT/FTO 1 SHANY 2006

10/579510

IN AN APPLICATION			BEALS,	BEALS, John Michael, et al.				
				Filing Date US Nat'l Entry (if applicable) Group			·	
		U	S. PATENT DO	OCUMENTS				
Examiner Cit Initials* No.		Document Number Number-Kind Code ² (if know	Publication MM-DD-1		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear	
	AA	US2002/164713	11-7-20	002 Chiro	n Corporation			
-	AB	US 6,716,626	04-06-2	004 Chiro	n Corporation	<u> </u>		
	AC	US2005/0048507	03-03-2	005 ZHON	NG, Mei			
	AD	US2005/037457	02-17-2	005 Chiro	n Corporation			
		FOR	EIGN PATENT	DOCUMENT	<u>'S</u>	1	_	
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Li Relevant Passages Figures App	or Relevant	T ⁶	
	BA	WO 01/18172	03-15-2001	Amgen, Inc.				

03-15-2001

05-10-2001

Atty. Docket No.

First Applicant

X-16280

			Beecham Corporation	
BD	WO 01/36640	05-25-2001	Chiron Corporation	
BE	WO 01/49849	07-12-2001	Zymogenetics, Inc.	
BF	WO 01/72957	10/04/2001	ITOH, Nobuyuki	
BG	WO 01/94587	12-13-2001	Incyte Genomics, Inc.	
ВН	WO 03/11213	02-13-2003	Eli Lilly and Company	
BI	WO 03/59270	07-24-2003	Eli Lilly and Company	

Curagen Corporation

Smithdline

Examiner
Signature

FEXAMINE: Initial if represe considerat, whether or not clarken is in conformance with MFEP 4699. Draw line through clarken if not in conformance and not considered. Include copy of this form with two communication not applicate.

Applicant's unique chains designation ammer (optional). ² See Kinds Codes of USPTO Parent Documents in agroupping only WPP 90.04. ² East of Title That Moved the descriment, by the two-keter code (WPPO Standard ST.). ² They Plangues of movement and extended in the final parent of the resign of the Emperor must perceive the variety number of the parent comman. ²-Stand of "Codes were by the agreement of the Codes of the Emperor must perceive the variety number of the parent comman. ²-Stand of "Codes were by the Standard ST., it is provide. ² Applicant so uplace a deed must be ref. English language Translation to standard. ²
Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Paren and Transman Office. ²
Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Paren and Transman Office. ²
Any comment on the amount of time you are required to complete this Standard Code. ²
Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Paren and Transman Office. ²
Any comment on the amount of time you are required to complete this Standard Code. ²
Any comment on the amount of time you are required to complete this Standard Code. ²
Any comment on the amount of the parent of the standard Code. ²
Any comment of the amount of the amount of the parent of the standard Code of

X-16280

10/579510

Sheet 2 of 2

	NON PATENT LITERATURE AND RESEASCH TO 16 MAY 2006				
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	. T ⁶		
	CA	NISHIMURA, et al., "Identification of a Novel FGF, FGF-21, Preferentially Expressed in the Liver", Biochimica et Biophysica Acta, 1492 (2000), 203-206.			

Examiner Signature	/Christine Saoud/	Date Considered	05/27/2008				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of							
this form with next communication to applicant.							

Inplicate visingle classification and religious market (priseas). See Kindic Oxford (ISTPO Paren Documents, as prescuping over WEP 901.04. Sector Office that should be document. By the view text Oxford (WIPO) Statutes 57.3. "See Auguste great or Accument, be the leadersh of the year of the religion of the Empartment may precede the version intellect of the guest or document." See the section of the Company of the religion of the Empartment or preceded the version of the Empartment of Empartment of the Empartment of Empartment of the Empartment of